Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Roche Holding, Adobe, McDonald, Deere & Co and BP p.l.c

by Zacks Equity Research

Roche Holding, Adobe, McDonald, Deere & Co and BP p.l.c are part of Zacks top Analyst Blog.

Sheraz Mian headshot

Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's

by Sheraz Mian

Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).

Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

by Zacks Equity Research

Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.

Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx

by Zacks Equity Research

Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.

Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.

Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.

Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.

ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.

    Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2

    by Zacks Equity Research

    Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.

    Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints

    by Zacks Equity Research

    Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.

    AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use

    by Zacks Equity Research

    AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.

    Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

    by Zacks Equity Research

    Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

    Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

    by Zacks Equity Research

    Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.

    Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates

    by Zacks Equity Research

    Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.

    Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?

    by Zacks Equity Research

    Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.

    Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD

    by Zacks Equity Research

    Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.

    BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

    Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug

    by Zacks Equity Research

    Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.

    Kinjel Shah headshot

    Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY

    by Kinjel Shah

    FDA grants priority review to Roche's (RHHBY) BLA for Lunsumio. AstraZeneca (AZN) announces a small acquisition. Pfizer (PFE) files NDA for Paxlovid.

      Roche's (RHHBY) Lunsumio Application Gets Priority Review

      by Zacks Equity Research

      Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.

      Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's

      by Zacks Equity Research

      The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).

      AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer

      by Zacks Equity Research

      The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast cancer.

      Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051

      by Zacks Equity Research

      The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.

      Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer

      by Zacks Equity Research

      Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.